Shortcut Navigation:

Breast Cancer News

In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.

ASCO Issues Guideline for Metastatic HER2-negative Breast Cancer

The American Society of Clinical Oncology, ASCO, released a new treatment guideline for HER2-negative breast cancer that has spread from the breast to nearby areas or distant parts of the body.

Final Results of TH3RESA Trial Confirm Effectiveness of T-DM1

Final results of the phase III TH3RESA trial confirm that the medicine T-DM1 extends progression-free survival, PFS, in people who have HER2-positive metastatic breast cancer that no longer responds well to first-line treatments, such as trastuzumab. PFS is the time from the start of treatment until the disease grows or spreads.

Early results of this study were presented at the European Cancer Congress, in Amsterdam, in the fall of 2013.

CLEOPATRA Final Results: Perjeta Extends Life Significantly

Final results from the CLEOPATRA trial were presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid at the end of September. The results show the combination of trastuzumab and pertuzumab, along with chemotherapy, lengthened the lives of women with HER2-positive metastatic breast cancer by a median 15.7 months. The increase is being called unprecedented.

Research May Mean Fewer Side Effects For Women With Bone Metastases

New findings may pave the way for people with stage IV breast cancer in the bones to receive bone-strengthening treatment less often. These results could mean decreased risk of side effects.

ASCO Issues First Guidelines for Metastatic HER2-positive Breast Cancer

To help doctors recommend treatment options based on research evidence and expert consensus, the American Society of Clinical Oncology released its first guidelines on treating metastatic HER2-positive breast cancer.

ASCO issued two clinical practice guidelines for this breast cancer type. One advises on systemic (whole body) therapies for HER2-positive breast cancer that has advanced outside of the breast, other than to the brain. The other recommends specifics on treating brain metastases.

Everolimus Plus Exemestane — A Possible First-Line Therapy for Metastatic Disease

Everolimus (Afinitor) and exemestane (Aromasin) taken at the same time may be an effective first-line treatment for hormone receptor-positive breast cancer that spread beyond the breast to other organs, after treatment with another aromatase inhibitor. This finding comes from a new analysis of data from the BOLERO-2 trial. 

Phase II Study Shows New Medicine May Slow Metastatic Breast Cancer

Research presented at the 2014 American Association for Cancer Research Annual Meeting suggests a new treatment pair may help double the time before estrogen receptor-positive, metastatic breast cancer grows or spreads. 

Study Finds Higher Dose of Fulvestrant Reduces Risk of Death

The final analysis of survival data from the Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) trial is encouraging. Researchers confirmed what was seen as a trend in their initial secondary analysis: postmenopausal women with metastatic, hormone-positive breast cancer lived longer when given twice the past standard amount of fulvestrant (Faslodex). 

Physical Activity After Breast Cancer May Improve Quality of Life

Exercising often after breast cancer treatment ends may help women improve their quality of life over time, say researchers from the University of Illinois at Urbana-Champaign.

Perjeta Safe and Effective for Older Women With HER2-positive Metastatic Breast Cancer

Women 65 and older received the same treatment benefit from the combination of pertuzumab (Perjeta), trastuzumab (Herceptin) and docetaxel (Taxotere) as women 64 and younger, a sub-analysis of CLEOPATRA trial data reveals. 

Denver, CO  ·  September 13, 2014

Join Your Community for Yoga on the Steps!

Close
close